The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis

Journal of Orthopaedic Surgery and Research

Lin Wang¹  Chuang Xiong¹  Chao Zhang¹  Hao Liang¹  Runhan Zhao¹  Xiaoji Luo² 

[1] Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, 400016, Chongqing, People’s Republic of China;Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, 400016, Chongqing, People’s Republic of China;Orthopedic Laboratory of Chongqing Medical University, Chongqing, People’s Republic of China;

关键词: Vascular endothelial growth factor;    Osteosarcoma;    Prognosis;    Meta-analysis;   

DOI  :  10.1186/s13018-021-02888-3

来源: Springer

【 摘 要 】

BackgroundIn recent years, numerous investigations have been conducted to determine the clinical significance and critical functions of vascular endothelial growth factor (VEGF) in various malignant cancers. The purpose of this meta-analysis was to comprehensively evaluate the prognostic and clinicopathological value of VEGF in patients with osteosarcoma.MethodsWe performed a systematic literature retrieval of available databases. Odds ratios (ORs) or standard mean difference (SMD) for clinicopathological parameters, hazard ratios (HRs) for overall survival and disease-free survival were calculated to assess the correlation between VEGF expression and prognosis in patients with osteosarcoma.ResultsA total of 22 studies with 1144 patients were included in our study. Pooled analyses showed that VEGF overexpression predicted worse overall survival (HR, 2.42; 95% CI, 1.87–3.11, p < 0.001) and disease-free survival (HR, 2.604; 95% CI, 1.698–3.995, p < 0.001), respectively. Furthermore, investigation regarding osteosarcoma clinicopathologic characteristics suggested that high VEGF expression was significantly associated with metastasis (OR, 4.39; 95% CI, 2.77–6.95; p < 0.001), clinical stage (OR, 0.73; 95% CI, 0.62–0.87; p < 0.001), and microvessel density (SMD, 3.33, 95% CI,1.57–5.10, p < 0.001), but not associated with tumor location, gender, age, local recurrence, and chemotherapy response.ConclusionOur meta-analysis findings suggest that elevated VEGF expression may be a predictive biomarker for poor prognosis and adverse clinicopathological characteristics in patients with osteosarcoma.

【 授权许可】

CC BY